These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 34058255)

  • 1. Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer With Brain Metastases.
    Yu F; Ni J; Zeng W; Zhou Y; Guo T; Zeng Y; Zhao Y; Li S; Li Y; Yang X; Zou L; Wang S; Liu Q; Li Y; Chu L; Chu X; Ye L; Yu W; Zhu Z
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):804-815. PubMed ID: 34058255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
    Zhao Y; Li S; Yang X; Chu L; Wang S; Tong T; Chu X; Yu F; Zeng Y; Guo T; Zhou Y; Zou L; Li Y; Ni J; Zhu Z
    Int J Cancer; 2022 Apr; 150(8):1318-1328. PubMed ID: 34914096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib for
    Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
    Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
    Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
    Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
    Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Tozuka T; Noro R; Mizutani H; Kurimoto F; Hakozaki T; Hisakane K; Naito T; Takahashi S; Taniuchi N; Yajima C; Hosomi Y; Hirose T; Minegishi Y; Okano T; Kamio K; Yamaguchi T; Seike M;
    Lung Cancer; 2024 May; 191():107540. PubMed ID: 38614069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases.
    Zhou J; Zhou Y; Sun Y; Xiao L; Lu H; Yin X; Fan K
    Front Oncol; 2023; 13():1259880. PubMed ID: 38313214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From
    Pike LRG; Miao E; Boe LA; Patil T; Imber BS; Myall NJ; Pollom EL; Hui C; Qu V; Langston J; Chiang V; Grant M; Goldberg SB; Palmer JD; Prasad RN; Wang TJC; Lee A; Shu CA; Chen LN; Thomas NJ; Braunstein SE; Kavanagh BD; Camidge DR; Rusthoven CG
    J Clin Oncol; 2024 Oct; 42(30):3606-3617. PubMed ID: 39047224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
    Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease.
    Zeng Y; Ni J; Yu F; Zhou Y; Zhao Y; Li S; Guo T; Chu L; Yang X; Chu X; Cai X; Zhu Z
    Radiat Oncol; 2020 Aug; 15(1):207. PubMed ID: 32854745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy.
    Guo T; Ni J; Yang X; Li Y; Li Y; Zou L; Wang S; Liu Q; Chu L; Chu X; Li S; Ye L; Zhu Z
    Int J Radiat Oncol Biol Phys; 2020 May; 107(1):62-71. PubMed ID: 31987959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study.
    Hori T; Yamamoto K; Ito T; Ikushima S; Omura T; Yano I
    Biol Pharm Bull; 2023; 46(6):788-795. PubMed ID: 37258143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
    Hyun DG; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
    PLoS One; 2020; 15(4):e0231546. PubMed ID: 32298306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration.
    Robledo KP; Lefresne S; Soon YY; Sahgal A; Pinkham MB; Nichol A; Soo RA; Parmar A; Hegi-Johnson F; Doherty M; Solomon BJ; Shultz DB; Tham IW; Sacher AG; Tey J; Leong CN; Koh WY; Huang Y; Ang YLE; Low J; Yong C; Lim MC; Tan AP; Lee CK; Ho C
    BMJ Open; 2024 Jul; 14(7):e078335. PubMed ID: 38969367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.